{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-013459","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.565280+00:00","generated_at":"2026-05-17T06:40:19.023045+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MIRA announces positive preclinical PTSD data for Ketamir-2 in rat model","bullets":["Ketamir-2 reversed stress-induced avoidance, anxiety, and despair in rats after 5 daily oral doses.","Results from Single Prolonged Stress model showed behavior normalized to non-stressed animal levels.","Ketamir-2 is also in a Phase 1 trial for neuropathic pain with a favorable safety profile to date.","DEA concluded Ketamir-2 is not a controlled substance under the Controlled Substances Act.","A larger follow-on PTSD study in animals is ongoing; results support further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-013459","json":"https://secwatch.observer/filing/0001493152-25-013459.json","markdown":"https://secwatch.observer/filing/0001493152-25-013459.md","text":"https://secwatch.observer/filing/0001493152-25-013459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225013459/0001493152-25-013459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225013459/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:40:19.023045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}